Aravive Stock Forecast, Price & News

-0.20 (-4.61 %)
(As of 07/29/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume76,319 shs
Average Volume383,333 shs
Market Capitalization$85.76 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ARAV News and Ratings via Email

Sign-up to receive the latest news and ratings for Aravive and its competitors with MarketBeat's FREE daily newsletter.

Aravive logo

About Aravive

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, HER negative breast cancer, uterine, pancreatic cancer, urothelial, and non-small-cell lung cancers. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain AVB-500 as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.34 out of 5 stars

Medical Sector

69th out of 2,214 stocks

Pharmaceutical Preparations Industry

30th out of 869 stocks

Analyst Opinion: 3.4Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Aravive (NASDAQ:ARAV) Frequently Asked Questions

Is Aravive a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aravive in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Aravive stock.
View analyst ratings for Aravive
or view top-rated stocks.

What stocks does MarketBeat like better than Aravive?

Wall Street analysts have given Aravive a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aravive wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Aravive?

Aravive saw a decrease in short interest during the month of July. As of July 15th, there was short interest totaling 777,900 shares, a decrease of 48.8% from the June 30th total of 1,520,000 shares. Based on an average daily trading volume, of 592,800 shares, the days-to-cover ratio is currently 1.3 days. Currently, 6.7% of the shares of the company are sold short.
View Aravive's Short Interest

When is Aravive's next earnings date?

Aravive is scheduled to release its next quarterly earnings announcement on Monday, August 2nd 2021.
View our earnings forecast for Aravive

How were Aravive's earnings last quarter?

Aravive, Inc. (NASDAQ:ARAV) announced its quarterly earnings results on Wednesday, May, 5th. The company reported ($0.44) EPS for the quarter, topping the Zacks' consensus estimate of ($0.45) by $0.01. The business earned $0.26 million during the quarter, compared to analysts' expectations of $0.57 million.
View Aravive's earnings history

How has Aravive's stock been impacted by COVID-19 (Coronavirus)?

Aravive's stock was trading at $4.99 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ARAV shares have decreased by 17.0% and is now trading at $4.14.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ARAV?

6 Wall Street analysts have issued 12-month price objectives for Aravive's shares. Their forecasts range from $20.00 to $30.00. On average, they expect Aravive's stock price to reach $25.20 in the next year. This suggests a possible upside of 508.7% from the stock's current price.
View analysts' price targets for Aravive
or view top-rated stocks among Wall Street analysts.

Who are Aravive's key executives?

Aravive's management team includes the following people:
  • Dr. Gail F. McIntyre, Pres, CEO & Director (Age 58, Pay $562.47k)
  • Mr. Vinay Shah, Chief Financial Officer (Age 59, Pay $481.99k)
  • Dr. Raymond Tabibiazar M.D., Advisor
  • Dr. Reshma Rangwala M.D., Ph.D., Chief Medical Officer (Age 43, Pay $144.07k)
  • Dr. Jeffrey L. Cleland, Co-Founder (Age 56)
  • Dr. Joshua Silverman Ph.D., Co-Founder
  • Joseph T. Schepers, VP of Investor Relations
  • Dr. Randy L. Anderson, Sr. VP of Data Sciences
  • Kenneth L. Guernsey, Sec.

Who are some of Aravive's key competitors?

What other stocks do shareholders of Aravive own?

What is Aravive's stock symbol?

Aravive trades on the NASDAQ under the ticker symbol "ARAV."

How do I buy shares of Aravive?

Shares of ARAV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aravive's stock price today?

One share of ARAV stock can currently be purchased for approximately $4.14.

How much money does Aravive make?

Aravive has a market capitalization of $85.76 million and generates $5.68 million in revenue each year. The company earns $-30,540,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis.

How many employees does Aravive have?

Aravive employs 17 workers across the globe.

What is Aravive's official website?

The official website for Aravive is

Where are Aravive's headquarters?

Aravive is headquartered at River Oaks Tower 3730 Kirby Drive Suite 1200, Houston TX, 77098.

How can I contact Aravive?

Aravive's mailing address is River Oaks Tower 3730 Kirby Drive Suite 1200, Houston TX, 77098. The company can be reached via phone at 936-355-1910 or via email at [email protected]

This page was last updated on 7/29/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.